@inproceedings{inproceedings, title = {{A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs}}, url = {{}}, year = {{2013}}, month = {{5}}, author = {{Wolin EM and Jarzab B and Eriksson B and Walter T and Toumpanakis C and Morse M and Tomassetti P and Weber M and Fogelman DR and Ramage J and Poon D et al}}, volume = {{31}}, journal = {{JOURNAL OF CLINICAL ONCOLOGY}}, issue = {{15}}, note = {{Accessed on 2025/04/11}}}